在胃肠道瘤中精确瘤学
Hiba Mechahougui1, Montemurro Michael2, Alex Friedlaender1,3
1Oncology Department, Geneva University Hospital, 1205 Geneva, Switzerland.
Current oncology (Toronto, Ont.)
|May 26, 2023
概括
胃肠道 stromal 瘤 (GIST) 在晚期的治疗选择有限. 新的基因组导向疗法和通过活检进行耐药性监测为GIST患者提供了改进的管理策略.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 遗传学 遗传学 是一个
背景情况:
- 胃肠道 stromal 瘤 (GIST) 是一种罕见的介质细胞瘤,占瘤的20%,占初级胃肠道癌症的1-2%.
- 虽然局部GIST的预后很好,但转移性疾病在历史上具有糟糕的结果,治疗选择有限,超出了二线治疗.
- 最近的进展已经建立了KIT或PDGFRA突变GIST的多种治疗线.
研究的目的:
- 审查目前GIST的流行病学和生物学.
- 讨论GIST的新兴和未来的管理策略.
- 强调基因组导向疗法在GIST治疗中的作用.
主要方法:
- 关于GIST流行病学,生物学和治疗的文献评论.
- 分析当前的治疗环境,包括有针对性的疗法 (TKI).
- 讨论诸如TKI阻力和潜在解决方案等挑战.
主要成果:
- 越来越多的治疗选择正在成为GIST的可用,由分子诊断驱动.
- 氨酸激酶抑制剂 (TKI) 是标准的治疗方法,但由于二次突变的耐药性是一个重大挑战.
- 正在研究具有更广泛的KIT抑制和组合疗法的新分子.
结论:
- GIST的管理正在迅速发展,重点是分子分析.
- 克服TKI耐药性的策略,包括连续活检和液体活检,至关重要.
- 基因组导向疗法和新型治疗组合有望改善先进GIST的结果.
关键词:
这是一款KIT KIT.根据PDGFR的规定.胃肠道 stromal 瘤的发生.伊马替尼布 (Imatinib) 的使用情况转移性胃肠胃炎 (GIST) 是一个转移性疾病.精确瘤学 精确瘤学雷戈拉芬尼布的使用情况苏尼提尼布 (sunitinib) 的使用方法铁氨基激酶抑制剂 铁氨基激酶抑制剂更多相关视频
05:16Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
Published on: February 19, 2022
6.0K
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.2K
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K